UTHRUNITED THERAPEUTICS Corpvs its industry peers
A metric-by-metric comparison of UNITED THERAPEUTICS Corp against iShares Biotechnology ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UTHR본 종목 | $22.0B#6 | 19.1x#2 | 3.7x#2 | 6.9x#3 | 10.6%#2 | 11.7%#5 | 46.9%#1 | 22.6%#4 | — | — | — | — |
| VRTX | $121.1B#3 | 28.3x#4 | 6.3x#3 | 10.1x#5 | 8.9%#4 | 838.1%#2 | 34.8%#2 | 20.4%#5 | 25.4%#2 | — | 4.4%#4 | — |
| GILD | $161.6B#2 | 17.7x#1 | 6.9x#4 | 5.5x#1 | 2.4%#6 | 1672.9%#1 | 34.0%#3 | 36.2%#2 | 21.6%#3 | — | 18.8%#3 | 2.5%#1 |
| AMGN | $207.9B#1 | 26.8x#3 | 22.6x#6 | 5.7x#2 | 10.0%#3 | 88.5%#4 | 24.7%#5 | 83.9%#1 | 15.3%#4 | — | 33.8%#1 | 2.5%#2 |
| ALNY | $27.5B#5 | 35.8x#5 | 20.3x#5 | 7.4x#4 | 65.2%#1 | 212.8%#3 | 13.5%#6 | 23.2%#3 | 150.5%#1 | — | -47.5%#5 | — |
| WAT | $37.0B#4 | 48.0x#6 | 2.4x#1 | 11.7x#6 | 7.0%#5 | 0.8%#6 | 25.4%#4 | 4.2%#6 | 3.5%#5 | 4#1 | 30.5%#2 | — |
Peer set: top holdings of IBB (iShares Biotechnology ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-08-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice